drugset / Trial / NCT02321111

The Role of TLR4 on Lipid-induced Insulin Resistance

NCT02321111

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) prevents lipid-induced insulin resistance in lean, normal glucose tolerant (NGT) subjects.

Timeline

Start
2015-01
Primary completion
2018-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eritoran Small molecule 12 mg Intravenous

Indications

No indication recorded.